Nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer
By developing 80bp nucleic acid aptamer for esophageal cancer detection, the problem of drug resistance in esophageal cancer treatment was solved, and high specific identification and combination of paclitaxel-resistant esophageal squamous cell carcinoma cells was achieved, and the treatment effect was improved. Diagnosis and treatment of similar diseases provide new technical ideas.
Patent Information
- Application Number
- CN202411187104.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
Existing esophageal cancer treatment drugs are difficult to distinguish between normal cells and malignant cells, resulting in nonspecific cytotoxicity, and cancer cells develop resistance to anti-tumor drugs, reducing the effect of chemotherapy.
A nucleic acid aptamer (V1 and V5) for detection of paclitaxel-resistant esophageal cancer with a length of 80 bp was developed. Nucleic acid aptamer that binds highly specific and highly affinity to paclitaxel-resistant esophageal squamous cell carcinoma cells was screened through Cell-SELEX technology. Used for detection and targeted therapy.
Preliminary demonstration that nucleic acid aptamers bind to specific proteins on the surface of paclitaxel-resistant esophageal squamous cell carcinoma, provides strategies to overcome esophageal cancer resistance, improves the therapeutic effect of esophageal cancer, and provides new for the diagnosis and treatment of other similar diseases. Technical ideas.
Smart Images

Figure CN118931910A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biomedical diagnosis and treatment of cancer, and specifically relates to a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer. Background Art
[0002] Esophageal cancer is a common gastrointestinal tumor. 95% of esophageal cancer cases are diagnosed as esophageal squamous cell carcinoma, which is characterized by high mortality and poor prognosis. Current treatments mainly include surgery, chemoradiotherapy, and immunotherapy. Due to the lack of targeting, these therapeutic drugs have difficulty distinguishing between normal cells and malignant cells, which can lead to nonspecific cytotoxicity. In addition, with the use of drugs, cancer cells often develop acquired resistance to anti-tumor drugs. For example, cancer cells exclude drugs, the DNA repair ability of cancer cells is enhanced, and the loss of cell apoptosis function will cause cancer cells to be insensitive to chemotherapy drugs, causing the treatment effect to be further reduced. Therefore, it is necessary to develop treatment strategies to overcome esophageal cancer resistance and improve the treatment effect of esophageal cancer.
[0003] Aptamers are short single-stranded DNA or RNA that can bind to target molecules with specificity and high affinity. Aptamers have the advantages of simple synthesis, flexible structure, easy modification, low immunogenicity, and access to hidden domains within small molecules or protein targets. They are also called "chemical antibodies", which makes aptamers a more favorable targeted therapy tool. Due to the above characteristics, aptamers play an important role in cancer diagnosis and delivery systems. For example, aptamers are labeled with fluorescent groups for detection and imaging of specific cells and coupled with drugs for targeted therapy. Therefore, screening out aptamers that can specifically identify paclitaxel-resistant esophageal cancer can provide certain targeted therapy tools for early diagnosis of paclitaxel-resistant esophageal cancer to overcome esophageal cancer resistance. Summary of the invention
[0004] The technical problem to be solved by the present invention is to overcome the existing defects and provide a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer, which lays a certain technical foundation for the treatment strategy of overcoming the drug resistance of esophageal cancer and improving the treatment effect of esophageal cancer, and can effectively solve the problems in the background technology.
[0005] To achieve the above object, the present invention provides the following technical solution: a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer, which is a nucleotide sequence of 80 bp in length, and its sequence is as follows (5'→3'): V1: CTTCCAGCCAGACCTCACTTGGGGAGAAGCAGGGGTATGGACTTCGACGTACTGGTTATAACGACGGTGTATGATGAGCG; or V5: CTTCCAGCCAGACCTCACTTAGATAACGAAAGAGATAGGGACTTAGATATGCTTTGTATACGACGGTGTATGATGAGCG.
[0006] The invention discloses an application of a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer in preparing a tumor detection reagent, wherein the tumor is paclitaxel-resistant esophageal squamous cell carcinoma.
[0007] Furthermore, the tumor cells are KYSE70 / PTX cells.
[0008] A detection method using a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer comprises the following steps: (1) Sample processing: pre-processing the samples to be tested; (2) Incubation and detection: The nucleic acid aptamer is incubated with the pre-treated sample to be tested. After the incubation, flow cytometry or laser confocal imaging analysis is performed.
[0009] Compared with the prior art, the beneficial effects of the present invention are: the nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer has the following advantages: The present invention is based on Cell-SELEX technology, and screened and obtained two nucleic acid aptamers that can bind to paclitaxel-resistant esophageal squamous cell carcinoma living cells with high specificity and high affinity, and preliminarily proved that these nucleic acid aptamers bind to proteins specifically expressed on the surface of paclitaxel-resistant esophageal squamous cell carcinoma. Therefore, based on the present application and further in-depth development of related molecular probes, a certain technical foundation can be provided for reversing the drug resistance of paclitaxel-resistant esophageal squamous cell carcinoma and improving the treatment effect of esophageal cancer, and new technical ideas and references can be provided for the diagnosis and treatment of other similar diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 This is a comparison chart of drug resistance detection of KYSE70 / PTX; Figure 2 This is the optimization diagram of primer annealing temperature at different temperatures; Figure 3 The results of enrichment detection of screening library by flow cytometry; Figure 4 This is a flow cytometry comparison of the binding ability of V1, V5 and KYSE70 / PTX; Figure 5 Schematic diagram of the secondary structure of V1 and V5; Figure 6 is the dissociation constant K between V1, V5 and target cell KYSE70 / PTX d Value determination results; Figure 7The ability of V1 and V5 to recognize KYSE70 / PTX and KYSE70 was tested by laser confocal imaging; Figure 8 Comparison of the binding ability of V1, V5 and target cell KYSE70 / PTX at different incubation temperatures; Fig. 9 This is a comparison chart of the binding specificity of V1 and V5 to different cells.
[0011] in, Figure 3-4 In the , FAM-labeled Random was used as the control probe; Figure 8-9 In the table, SBR stands for combined signal-to-background ratio. DETAILED DESCRIPTION
[0012] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0013] In one aspect of the present invention, a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer is a nucleotide sequence of 80 bp in length, and its sequence is as follows (5'→3'): V1: CTTCCAGCCAGACCTCACTTGGGGAGAAGCAGGGGTATGGACTTCGACGTACTGGTTATAACGACGGTGTATGATGAGCG; or V5: CTTCCAGCCAGACCTCACTTAGATAACGAAAGAGATAGGGACTTAGATATGCTTTGTATACGACGGTGTATGATGAGCG.
[0014] Another aspect of the present invention is the use of a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer in preparing a tumor detection reagent, wherein the tumor is paclitaxel-resistant esophageal squamous cell carcinoma, and the tumor is KYSE70 / PTX cells.
[0015] Experimental Example 1 Detection of drug resistance of KYSE70 / PTX in esophageal squamous cell carcinoma cells The cells were plated on a 96-well cell culture plate and cultured in a cell culture incubator at 37°C and 5% CO2 for 24 hours. 100uL of a series of paclitaxel concentration gradient culture media (4ng / ml, 40ng / ml, 400ng / ml, 4000ng / ml, 10000ng / ml) was added to each well of the cell culture plate. Each group was set up with 5 replicate wells and cultured in the incubator for 24 hours. Cells cultured without paclitaxel culture media were set up as a control group. The cell waste liquid was discarded, and the CCK-8 reagent was diluted with incomplete 1640 culture media. 100μl of the diluted solution was added to each well and cultured for 2 hours. Finally, the absorbance value was detected with an enzyme marker to evaluate drug resistance. Figure 1 As shown, with the increase of paclitaxel concentration, the survival rate of positive sieve cells remained basically unchanged, while the survival rate of negative sieve cells decreased significantly.
[0016] Experimental Example 2 The method for screening nucleic acid aptamers for detecting paclitaxel-resistant esophageal cancer comprises the following steps: (1) Starting library and primer design The starting library contains 80 bases, a random sequence of 40 bases in the middle, and primer sequences of 20 bases at both ends for PCR amplification; when synthesizing primers, the 5' end of the forward primer is labeled with a FAM fluorescent group for flow cytometry monitoring, and the 5' end of the reverse primer is labeled with biotin to prepare ssDNA; the principles followed in designing primers are: the primer cannot form self-dimers, and the complementary bases formed by itself or between the two cannot exceed 3 pairs; the 5' end cannot be a G base, which will quench the fluorescent substance; the 3' end cannot be a G base, otherwise it will be difficult to deprotect the synthesis; the annealing temperature of the two primers should be between 55-65℃, the GC% content should be greater than 50%, and the annealing temperature difference of the two primers to the template should not be much different; in order to improve the yield and purity of the PCR amplification product, the annealing temperature of the primers needs to be optimized. After Oligo Analyzer analysis showed that the annealing temperature of the primer pair was about 57°C, so the annealing temperature was set to 56°C-65°C with an interval of 1°C; amplification was performed for 24 cycles; like Figure 2 As shown, at 59°C, the bands are clear, bright, less diffuse, and no non-specific amplification, so 59°C is selected as the optimal annealing temperature; the specific library construction and primer synthesis were completed and provided by Sangon Biotech Co., Ltd. (Shanghai, China); the specific sequences are as follows: Each single-stranded DNA is represented by: 5'-CTTCCAGCCAGACCTCACTT-N40-ACGACGGTGTATGATGAGCG-3'; The forward primer is represented as: 5'-FAM-CTTCCAGCCAGACCTCACTT-3'; The reverse primer is represented as: 5'-Biotin-CGCTCATCATACACCGTCGT-3'; (2) Cell-SELEX screening Before screening, 50 nmol of the single-stranded DNA library and 50 μL of binding buffer (BB) were placed in a 95°C water bath for pretreatment for 5 min, and then cooled on ice for 10 min. After cooling, 900 μL of pre-cooled BB was added for standby use. Forward screening was used in the first to third rounds. KYSE70 / PTX cells were incubated with the Random sequence to remove non-specific binding, and then the Random sequence was discarded and incubated on ice with the pre-treated library for 60 min. After incubation for 60 min, the waste liquid was poured out and washed with pre-cooled Washing Buffer (Washing Buffer, WB) wash the cells to wash away the unbound ssDNA sequences; then add sterile water to the culture dish, scrape the cells with a scraper on ice, collect the supernatant to obtain the DNA bound to the positive screening cells; in the fourth round, reverse screening is introduced, and KYSE70 cells are incubated with Random sequences to remove non-specific binding. After pre-treatment of the single-stranded DNA library collected in the third round and incubated with KYSE30 cells for 30 minutes, the supernatant is collected to obtain the DNA library that is not bound to the reverse screening cells, and the library is incubated in the positive screening cells KYSE70 / PTX, the same as the forward screening; In order to obtain aptamers with stronger binding ability to target cells, screening pressure can be applied during the screening process, such as: reducing the amount of library input; increasing the reverse screening time and reducing the forward screening time; increasing the number of washes, wash time, and wash volume; gradually increasing the WB temperature for washing from 4°C to room temperature, etc. (3) Screening library enrichment detection Library enrichment was detected by flow cytometry; well-growing KYSE70 / PTX and KYSE70 cells were digested with enzyme-free digestion solution, the cells were collected into centrifuge tubes, the cells were resuspended with an appropriate amount of BB solution, 100 μL of cell suspension was taken, mixed with 100 μL of BB containing 50 pmol of libraries enriched in different rounds, and incubated on ice for 40 min, with the same operation and the same concentration, and the FAM-labeled Random sequence was used for control; after the incubation was completed, the unbound library was washed away by centrifugation, the cells were resuspended in a flow tube with 400 μL of BB, and the samples were measured in a flow cytometer; (4) Screening enrichment results like Figure 3As shown in the figure, with the increase of screening rounds, the fluorescence value of KYSE70 / PTX binding to the library continued to increase and reached saturation at the 12th round; and with the increase of screening rounds, the fluorescence value of the library binding to KYSE70 was lower; this shows that during the screening process, the library was enriched and maintained good binding specificity with the positive screening cells; (5) High-throughput sequencing and sequence analysis The selected library was sent to Sangon Biotech (Shanghai) Co., Ltd. for high-throughput sequencing. After sequencing, the nucleic acid aptamers with a repeat number greater than 500 were selected for homology comparison and phylogenetic tree analysis using DNAMAN6.0 software. Based on the analysis results, 6 sequences (V1, V2, V3, V5, V6, and V8) were finally selected for synthesis and labeled with a FAM group at the 5' end; Figure 4 As shown in FIG. 1 , through flow cytometry analysis, among the candidate sequences, V1 and V5 can better bind to the target cells and do not bind to the control cells, so V1 and V5 are selected for subsequent experiments; finally, with the help of NUPACK software, the structures of V1 and V5 determined above are analyzed and simulated, and their secondary structures are shown in FIG. Figure 5 As shown; The specific sequence is (5'→3'): V1: CTTCCAGCCAGACCTCACTTGGGGAGAAGCAGGGGTATGGACTTCGACGTACTGGTTATAACGACGGTGTATGATGAGCG; V5: CTTCCAGCCAGACCTCACTTAGATAACGAAAGAGATAGGGACTTAGATATGCTTTGTATACGACGGTGTATGATGAGCG.
[0017] Experimental Example 3 Based on the screening results, the specific performance of nucleic acid aptamers V1 and V5 was further measured and analyzed. The relevant experimental process and results are briefly introduced as follows.
[0018] (1) Affinity determination of V1, V5 and KYSE70 / PTX The well-growing KYSE70 / PTX cells were digested with enzyme-free digestion solution, and the cells were collected into centrifuge tubes. Different incubation systems were configured to make the concentrations of nucleic acid aptamers 0nM, 5nM, 10nM, 25nM, 50nM, 100nM, 250nM, and 500nM. Each concentration was repeated 3 times and incubated on ice for 40min. The same operation and the same concentration were used as a control with the FAM-labeled Random sequence. After the incubation was completed, the unbound V5 was washed away by centrifugation, and the cells were resuspended in a flow tube with 400μL of BB and measured in a flow cytometer. The Mean-FI value measured by the flow cytometer was used as the ordinate and the concentration was used as the abscissa. The dissociation curve was simulated using the single-point adsorption equation Y=BmaxX / (Kd+X) to measure the equilibrium dissociation constant of V1 and V5 binding to the target cells.
[0019] like Figure 6 As shown, the specific dissociation curve and Kd value results are as follows: The fitted equation for the binding of V1 to KYSE70 / PTX cells was Y=1163*X / (65.6+X), and the dissociation constant Kd value was 65.6±12.1nM; the fitted equation for the binding of V5 to KYSE70 / PTX cells was Y=681*X / (45.4+X), and the dissociation constant Kd value was 45.4±18.7nM.
[0020] (2) Confocal laser scanning verifies the binding of V1 and V5 to KYSE70 / PTX The target cells KYSE70 / PTX and the control cells KYSE70 were passaged into a confocal imaging cell culture dish until the cells adhered to the wall, the waste liquid was discarded, the cells were washed 3 times with WB, 2 mL each time, 200 μL of 250 nM aptamer sequence was added to the confocal dish, and incubated on ice for 40 min; the same operation and the same concentration were used for control with FAM-labeled Random sequence; after the incubation, the aptamer sequence was discarded, the cells were washed 3 times with WB, and an appropriate amount of PBS solution was added to the dish to keep it moist for confocal imaging.
[0021] like Figure 7 As shown, the results showed that V1 and V5 had stronger fluorescence signal values for target cell KYSE70 / PTX binding, and had better ability to identify target cells, but almost did not bind to control cell KYSE70. The nucleic acid aptamer bound to the surface of the target cell membrane. Therefore, it was preliminarily speculated that the target of the nucleic acid aptamer binding to the cell was the cell membrane surface molecule.
[0022] (3) Effect of temperature on the binding ability of V1 and V5 The well-growing KYSE70 / PTX cells were digested with enzyme-free digestion solution, and the cells were collected into a centrifuge tube, mixed with 100 μL of BB containing 50 pmol of nucleic acid aptamer sequence, and incubated at 4°C, 25°C, 37°C, and 40°C for 40 min respectively; the same operation and the same concentration were used as a control with a FAM-labeled Random sequence; after the incubation was completed, the unbound V1 and V5 were washed away by centrifugation, and the cells were resuspended in a flow tube with 400 μL of BB, and the samples were measured in a flow cytometer to determine the signal-to-background ratio of the binding ability of the nucleic acid aptamer to the cells at 4°C, 25°C, 37°C, and 40°C.
[0023] like Figure 8 As shown in the figure, the binding ability decreased slightly with the increase of temperature, but still had strong binding ability, especially at 37°C, V1 and V5 still had good binding ability with KYSE70 / PTX cells. This result showed that the nucleic acid aptamer had the potential for in vivo application.
[0024] (4) Investigation of V5 binding specificity Well-growing esophageal cancer cells KYSE70 / PTX, KYSE510, KYSE410, KYSE150, KYSE450, KYSE30, KYSE70, EC109, breast cancer cells MCF-7, lung cancer cells EBC-1, A549, liver cancer cells HepG2, gastric cancer cells HGC-27, cervical cancer cells Hela, normal esophageal epithelial cells Het-1A and normal liver cells HL-7702 were digested with enzyme-free digestion solution, and the cells were collected into centrifuge tubes, mixed with 100 μL of BB containing 50 pmol of nucleic acid aptamer sequence, and incubated on ice for 40 minutes; the same operation and the same concentration were used for control with FAM-labeled Random sequence; after the incubation was completed, the unbound V1 and V5 were washed away by centrifugation, and the cells were resuspended in a flow tube with 400 μL of BB, and the fluorescence intensity was measured in a flow cytometer and the signal-to-background ratio was calculated.
[0025] like Fig. 9 As shown in the figure, through flow cytometry analysis, V1 and V5 have good binding ability with KYSE70 / PTX cells, but not with other non-resistant cancer cell lines and normal cell lines. The results show that nucleic acid aptamers V1 and V5 have good specificity for resistant esophageal cancer cells and can be used in the detection of paclitaxel-resistant esophageal squamous cell carcinoma.
[0026] In the experimental examples of the present invention, KYSE70 / PTX, KYSE70 and other types of cells in the experimental examples were provided by the Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University; paclitaxel-resistant esophageal squamous cell carcinoma cells KYSE70 / PTX were cultured with complete RPMI 1640 medium containing a small amount of PTX to maintain the drug resistance of the resistant cells; esophageal squamous cell carcinoma cells KYSE70 and other types of cells in this study were cultured with complete RPMI 1640 medium or DMEM medium, and all cells were placed in a constant temperature incubator at 37°C and 5% CO2 for culture.
[0027] The above descriptions are merely embodiments of the present invention and are not intended to limit the patent scope of the present invention. Any equivalent structure or equivalent process transformation made using the contents of the present invention specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present invention.
Claims
1. A nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer, characterized in that: It is a nucleotide sequence of 80 bp in length, and its sequence is as follows (5'→3'): V1: CTTCCAGCCAGACCTCACTTGGGGAGAAGCAGGGGTATGGACTTCGACGTACTGGTTATAACGACGGTGTATGATGAGCG; or V5: CTTCCAGCCAGACCTCACTTAGATAACGAAAGAGATAGGGACTTAGATATGCTTTGTATACGACGGTGTATGATGAGCG.
2. Use of a nucleic acid aptamer for detecting paclitaxel-resistant esophageal cancer according to claim 1 in the preparation of a tumor detection reagent, wherein the tumor cells are KYSE70 / PTX cells.
